SLL Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about SLL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 2

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center230 enrolled8 locationsNCT03824483
Recruiting
Phase 2

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.100 enrolled18 locationsNCT07221500
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Early Phase 1

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
National Heart, Lung, and Blood Institute (NHLBI)30 enrolled1 locationNCT07428707
Recruiting
Phase 3

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled52 locationsNCT05947851
Recruiting
Phase 1

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
H. Lee Moffitt Cancer Center and Research Institute100 enrolled1 locationNCT07030400
Recruiting
Phase 2

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL+4 more
Zulfa Omer22 enrolled1 locationNCT07108998
Recruiting
Phase 2

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

CLL/SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland60 enrolled18 locationsNCT04523428
Recruiting

LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
IRCCS Azienda Ospedaliero-Universitaria di Bologna350 enrolled1 locationNCT07313982
Recruiting
Phase 2

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie110 enrolled31 locationsNCT02966756
Recruiting

Registry of the German CLL Study Group

CLLT-LGL LeukemiaNK-LGL Leukemia+5 more
German CLL Study Group8,000 enrolled1 locationNCT02863692
Recruiting
Phase 2

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Dana-Farber Cancer Institute45 enrolled4 locationsNCT05168930
Recruiting
Phase 1

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

CLL/SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)
Lomond Therapeutics Holdings, Inc.66 enrolled4 locationsNCT06708897
Recruiting
Phase 2

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
The First Affiliated Hospital with Nanjing Medical University79 enrolled1 locationNCT06958705
Recruiting
Phase 1Phase 2

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+5 more
CRISPR Therapeutics AG120 enrolled7 locationsNCT05643742
Recruiting
Phase 2

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia (SLL)
M.D. Anderson Cancer Center40 enrolled1 locationNCT06967610
Recruiting
Phase 2

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)
Massachusetts General Hospital40 enrolled2 locationsNCT06849713
Recruiting
Phase 3

Global Trial in APG2575 for Patients With CLL/SLL

CLL/SLL
Ascentage Pharma Group Inc.400 enrolled2 locationsNCT06104566
Recruiting
Phase 2

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL/SLL+1 more
Zulfa Omer34 enrolled1 locationNCT06978088